Citadel Advisors’s Abivax ABVX Stock Holding History

Citadel Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60.6M	Sell	544,338 -19,409	-3%	-$2.3M	0.01%	1182
2025 Q4	$76M	Sell	563,747 -118,038	-17%	-$12.9M	0.01%	1058
2025 Q3	$57.9M	Sell	681,785 -570,472	-46%	-$35M	0.01%	1244
2025 Q2	$9.58M	Sell	1,252,257 -121,603	-9%	-$793K	﹤0.01%	3087
2025 Q1	$8.59M	Buy	1,373,860 +518,184	+61%	+$3.51M	﹤0.01%	3060
2024 Q4	$6.26M	Buy	855,676 +389,247	+83%	+$3.58M	﹤0.01%	3612
2024 Q3	$5.37M	Buy	466,429 +11,669	+3%	+$140K	﹤0.01%	3830
2024 Q2	$6.01M	Sell	454,760 -96,750	-18%	-$1.38M	﹤0.01%	3462
2024 Q1	$7.89M	Sell	551,510 -181,357	-25%	-$2.34M	﹤0.01%	3267
2023 Q4	$7.84M	Buy	+732,867	New	+$7.47M	﹤0.01%	3163

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Citadel Advisors's ABVX Position: Q1 2026 in Review

Citadel Advisors reduced its Abivax (ABVX) stake by 3.4% in Q1 2026, selling an estimated $2.3M and leaving 544,338 shares worth $60.6M. The position accounts for 0.01% of the portfolio, ranked #1182.

Citadel Advisors first reported a position in ABVX in Q4 2023 and has held it in 10 quarters since. The position peaked at $76M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

Citadel Advisors held 544,338 shares of Abivax worth $60.6M as of Q1 2026.
Citadel Advisors sold 19,409 Abivax shares in Q1 2026, an estimated $2.3M.
Abivax made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1182 holding.
Citadel Advisors first reported a position in Abivax in Q4 2023 and has held it in 10 quarters since.
Citadel Advisors's Abivax position peaked at $76M in Q4 2025.
254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.